Mild to Moderate Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

  • Published Date : April 9, 2025
  • Updated On : December 10, 2025
  • Pages : 154

Mild to Moderate Asthma Market Outlook

Thelansis’s “Mild to Moderate Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mild to Moderate Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Mild to Moderate Asthma Overview

Mild to moderate asthma represents a chronic inflammatory disease of the respiratory system, characterized by bronchial hyperreactivity and episodes of reversible airway obstruction. The root cause of the disease is a sustained immune response in the bronchial mucosa, where certain exposures (e.g., allergens, cold air, viruses) lead to smooth muscle contraction, swelling of the mucosa, and increased secretion of mucus. The clinical picture is a quite stereotypical combination of wheezing, breath shortness, and chest tightness, which, nevertheless, if the underlying inflammation remains untreated, still poses a great risk of sudden, severe attacks even when labeled “mild” or “moderate”. The current treatment approach has completely abandoned the use of intermittently administered bronchodilator monotherapy towards the prompt initiation of inhaled corticosteroids (ICS), either alone or combined with long-acting beta agonists (LABA), for the purpose of long-term stabilization and avoidance of permanent structural changes in the airways. On the other hand, worldwide asthma care keeps being limited due to poor patient compliance and incorrect use of the inhaler device, thereby emphasizing the urgent requirement for simplified dosing schedules and improved patient education to unlock the full potential of treatment and achieve the desired level of disease control.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025–2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…
 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)

Frequently asked questions